



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Reviewer's code: 02527733

SPECIFIC COMMENTS TO AUTHORS

This conventional review focus one treatment of HCC in patinets with PVTT. Though the review is well written, I have the following concerns.

1. The topic is not new. Too many similar reviews have been published focus on the same topic.

We are aware of the existence of other reviews on this subject. However, ours is more recent and updated and represents a detailed revision of all published studies on each treatment option for portal vein tumor thrombosis For these reasons, we think that the paper will be a useful tool for medical doctors involved in the management of this difficult clinical issue.

2. Hepatic resection is still one of main treatment for patients with HCC involving PVTT. And so many high quality evidence with large sample size have been published. Such as (Hepatology. 2019 May;69(5):2076-2090.) (Hepatology. 2018 Sep;68(3):977-993).

We thank the reviewer for this observation. We commented these papers in page 19 lines 32-33 and page 20 lines 1-10.

The authors mainly focus on sorafenib, which has only 10% efficacy for such patients.

Unfortunately, although the efficacy of sorafenib is limited in these patients, it remains the only approved chemotherapy treatment for patients with compensated liver disease and advanced hepatocellular carcinoma extensively involving the portal vein system. However, we have discussed in depth all the other available treatment options, providing comparisons and detailed description of the outcomes.

They described some case reports as evidence. I suggest they cite some high quality



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

evidence (J Hepatol. 2019;70(4):684-691) and some comments (J Hepatol 2016;65(5):1057-1058)

Thanks to the Reviewer for this suggestion. We eliminated the discussion of case reports and added the cited papers in the text (page 7 lines 21-32, page 23 lines 1-15).



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Reviewer's code: 03261461

SPECIFIC COMMENTS TO AUTHORS

well written systematic review on very hot topic in HCC that deserve publication just one comment too long references section 182 reference!

Thanks to the Reviewer for his appreciation. The number of references is justified by the breadth of the subject and we believe that it is necessary for a detailed analysis of the published data.